The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming ...
6d
Hosted on MSNEU’s Clinical Trials Regulation comes into full forceThe ruling requires all trials across the EU to be filed through the European Medicines Agency’s digital filing system.
The government agency says X no longer suits its communication needs.
The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...
In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...
If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.
2d
GlobalData on MSNItalian charity seeks EMA approval for rescued gene therapyTelethon Foundation is seeking approval for a gene therapy to treat the rare disease Wiskott-Aldrich syndrome.
Fondazione Telethon, an Italian biomedical charity focused on rare genetic diseases, has submitted a Marketing Authorization ...
Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...
The European Medicines Agency (EMA) has decided to stop using the social media platform X due to content concerns and will instead use Bluesky. This move aligns with other organizations stepping back ...
As users continue to leave X (formerly Twitter) en masse, many in favor of the newer Bluesky platform, the European Medicines ...
Ocugen (OCGN) announced that the European Commission has provided a positive opinion from the EMA’s, or European Medicines Agency’s, Committee ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results